(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 December 2007 (06.12.2007)

PCT

(10) International Publication Number
WO 2007/139941 A2

(51) International Patent Classification:
C07K 14/43 (2006.01)

(21) International Application Number:
PCT/US2007/012499

(22) International Filing Date: 25 May 2007 (25.05.2007)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/808,810 26 May 2006 (26.05.2006) US

(71) Applicant *(for all designated States except US)*: **AMYLIN PHARMACEUTICALS, INC.** [US/US]; 9360 Towne Centre Drive, San Diego, Ca 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **GHOSH, Soumitra, Shankar** [US/US]; 9360 Towne Centre Drive, San Diego, Ca 92121 (US). **LEWIS, Diana, Y.** [US/US]; 9360 Towne Centre Drive, San Diego, Ca 92121 (US). **JANSSEN, Samuel** [NL/US]; 9360 Towne Centre Drive, San Diego, Ca 92121 (US). **SRIVASTAVA, Ved** [US/US]; 9360 Towne Centre Drive, San Diego, Ca 92121 (US). **LIU, Que** [CA/US]; 9360 Towne Centre Drive, San Diego, Ca 92121 (US). **JODKA, Carolyn, M.** [US/US]; 9360 Towne Centre Drive, San Diego, Ca 92121 (US). **SOARES, Christopher, J.** [US/US]; 9360 Towne Centre Drive, San Diego, Ca 92121 (US). **LIN, Qing** [US/US]; 9360 Towne Centre Drive, San Diego, Ca 92121 (US).


(74) Agents: **BUTLER, James, E.** et al.; Amylin Pharmaceuticals Inc., 9360 Towne Centre Drive, attn: Patent Department, San Diego, CA 92121 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) Title: COMPOSITION AND METHODS FOR TREATMENT OF CONGESTIVE HEART FAILURE



Points represent mean ± sd. Peptide was injected IP at t=0 immediately following baseline sample into 2-hour fasted NIH/Swiss mice.
Samples were taken at t= 30, 60, 120, 180 and 240 min.
Blood glucose was measured with a OneTouch® Ultra® (LifeScan, Inc., a Johnson & Johnson Company, Milpitas, CA)

* p<0.05 vs. vehicle control; ANOVA, Dunnett's test

(57) Abstract: Provided herein is the use of GLP-1 molecules or agonists and analogs thereof, and the use of exendin molecules or agonists and analogs thereof, including their derivatives and active fragments, for the prevention or treatment of congestive heart failure. Pharmaceutical compositions for use in the methods described herein are also disclosed. Further provided are compositions and methods for the treatment and/or prevention of diabetes mellitus, hyperglycemia, insulin resistance and obesity, and for the reduction of food intake and suppression of appetite of subjects.

WO 2007/139941 A2

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *without international search report and to be republished upon receipt of that report*

— *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.